Epizyme Announces Closing of Common Stock Offering

CAMBRIDGE, Mass.--()--Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced that the underwriters for its recently completed underwritten public offering of common stock have partially exercised their option to purchase additional shares of common stock from Epizyme. The underwriters purchased 701,448 shares from Epizyme at the public offering price of $20.75 per share, less underwriting discounts.

The aggregate net proceeds before expenses to Epizyme from the offering are approximately $130.7 million, after deducting underwriting discounts and commissions.

Leerink Partners LLC, Cowen and Company, LLC and RBC Capital Markets, LLC served as joint book-running managers for the offering. JMP Securities LLC served as lead manager for the offering, and SunTrust Robinson Humphrey, Inc. and Mizuho Securities USA Inc. were co-managers for the offering.

A shelf registration statement relating to the shares of common stock offered in the public offering described above was filed with the Securities and Exchange Commission (SEC) on June 12, 2014 and declared effective by the SEC on June 27, 2014. The offering was made only by means of a prospectus and prospectus supplement that form a part of the effective registration statement. Copies of the prospectus supplement relating to the offering may be obtained for free by visiting EDGAR on the SEC website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the securities offered may also be obtained by contacting Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, email: Syndicate@Leerink.com, phone: (800) 808-7525 ext. 6142; Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, phone: (631) 274-2806, fax (631) 254-7140; or RBC Capital Markets, LLC, 200 Vesey Street, 8th Floor, New York, NY 10281-8098; Attention: Equity Syndicate; phone: (877) 822-4089; Email: equityprospectus@rbccm.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Epizyme, Inc.

Epizyme, Inc. is a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients.

Contacts

Epizyme, Inc.
Media/Investors:
Manisha Pai, 617-229-7560
mpai@epizyme.com

Epizyme, Inc.